![]() Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a company developing biological and cellular therapeutics for difficult-to-treat cancers. | EnGeneIC EnGeneIC is a biopharmaceutical company focused on developing its proprietary EDV nanocell platform. | ![]() Alchemab Therapeutics Alchemab Therapeutics is a biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies. | ![]() Amunix Pharmaceuticals Amunix Pharmaceuticals is a biopharmaceutical company focused on immuno-oncology. | ![]() C4 Therapeutics C4 Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation. | |
Founding Date | Founding Date 2017 | Founding Date 2001 | Founding Date 2019 | Founding Date 2006 | Founding Date 2015 |
Type | Type Private | Type Private | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Lexington, US HQ | Locations Lane Cove West, AU HQ New York, US | Locations London, GB HQ Babraham, GB | Locations South San Francisco, US HQ | Locations Watertown, US HQ |
Employees | Employees 12 | Employees 43 | Employees 512% decrease | Employees 42 | Employees 1045% decrease |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 150k (about 9 years ago) | Latest funding round $ 71.8m (about 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 21.1m | Total funding raised $ 71.8m | Total funding raised $ 190m | Total funding raised $ 223m |
EnGeneIC is a biopharmaceutical company focused on developing its proprietary EDV nanocell platform.
View company
Alchemab Therapeutics is a biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies.
View company
Amunix Pharmaceuticals is a biopharmaceutical company focused on immuno-oncology.
View company
C4 Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation.
View company